MDFA is Australia’s largest source of research funding in the field of macular disease outside of government.
Spatial transcriptomics in diabetic macular ischaemia
MDFA is Australia’s largest source of research funding in the field of macular disease outside of government
Composition and functionality of high-density lipoprotein in age-related macular degeneration and a high-risk disease phenotype
Redefining macular disease diagnosis to improve access to emerging therapies
Investigating mitochondrial dysfunction in macular degeneration – towards new treatments and biomarkers
A stem-cell derived model of geographic atrophy age-related macular degeneration for mitochondrial-focused drug screening It is now consensus
Evaluating the potential of hyperspectral imaging for detecting and monitoring geographic atrophy Accurate monitoring of
One of Australia’s best known personalities Ita Buttrose has called on State, Territory and Federal Governments to do more for older Australians who are at risk of going blind.
Research update with Macular Disease Foundation Australia Grant Recipient, Professor Alice Pébay: webinar
Vabysmo is a new treatment for age-related macular degeneration and diabetic macular oedema and is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia
MDFA 2022 research update
We aim to respond to your request by the next business day. If you require assistance sooner, please call our National Helpline on 1800 111 709 (Monday - Friday 9-5pm AEST).
If your query is about an eye emergency - including sudden changes to your vision or eye pain - please contact your optometrist or ophthalmologist as soon as possible.Great!